| OVERVIEW OF BIOLOGICS AND BIOSIMILARS | ||
|---|---|---|
|
Drugs are typically manufactured through chemical In contrast, biologics are manufactured in living |
||
| Biologics | Biosimilars | |
| Definition |
• A virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings Continue Reading • Referred to as the reference, pioneer, or innovator biologic |
• The biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences* between the biological product and the reference product in terms of the safety, purity, and potency of the product • Referred to as follow-on biologic |
| Properties |
• Derived from living sources such as cells • Complex mixtures whose active ingredients (usually proteins) are hundreds of times larger than the compounds found in most pills • Mostly given by injection due to unstable environmental conditions |
• The active ingredient of biosimilars closely resemble the reference biologic • However, they are not identical, generic equivalents due to differences in manufacturing processes, protein source, and extraction/purification processes |
| Approval Process |
• Submitted through the BLA process • Requirements: º Applicant information: Includes name and addresses of manufacturing facilities º Product/Manufacturing information: Source material/raw material; manufacturing process and controls; formulation; facility information; contamination/cross-contamination information; environment assessment or categorical exclusion º Pre-clinical studies: Safety, efficacy, and use º Clinical studies: Safety, efficacy, and use º Labeling: Safety, efficacy, and use |
• 2012 FDA Draft Guidance recommends a stepwise approach to demonstrate biosimilarity, submitted through an abbreviated BLA • Requirements (unless FDA deems unnecessary): º Structural analyses: Determine structural characteristics of the protein, post-translational modifications, and/or other potential variants º Functional assays: Evaluate the pharmacologic activity of the protein (eg, potency and MOA) º Animal studies: Include toxicity, PK and PD measures, and immunogenicity º Clinical studies: Human pharmacology data, clinical immunogenicity assessment, and clinical safety and efficacy data to demonstrate safety, purity, and potency for the condition(s) the reference product is licensed and intended to be used for |
| Pharmaco– vigilance |
• Typically required to have postmarketing safety monitoring • Includes the detection, assessment, understanding and prevention of adverse effects after the launch of the biologic onto the market |
• Biosimilars should include postmarketing surveillance to address immunogenicity and potential rare adverse events when seeking approval • May undergo more strict monitoring due to limitations of clinical data compared to the reference product |
| CLINICAL CONSIDERATIONS | ||
| Substitution: The FDA allows for generic substitution of chemical drugs if two products can be deemed therapeutically equivalent. Due to the complex nature of biologics and the potential for differing properties and characteristics forming between biologics and their respective biosimilars, it is important to make informed decisions about substituting biologics. | ||
| NOTES | ||
|
Key: BLA = biologics license application; MOA = mechanism of action; PD = pharmacodynamic; PK = pharmacokinetic *Clinically meaningful differences could include a difference in the expected range of safety, purity, and potency of the proposed and reference products. By contrast, slight differences in rates of occurrence of adverse events between the two products ordinarily would not be considered clinically meaningful differences |
||
| REFERENCES | ||
|
1. U.S. Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product-Draft Guidance. U.S. Food and Drug Administration. [Online] February 2012. http://www.fda.gov/downloads/Drugs/GuidanceCompliance 2. U.S. Food and Drug Administration. Biologics License Applications (BLA) Process (CBER). U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBlood 3. Production Assistance for Cellular Therapies. The Biologics License Application Process. National Heart Lunch and Blood Program. https://secure.emmes.com/pactweb/system/files/cber101032204ry.pdf. March 31, 2004. Accessed October 10, 2013. 4. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncology. 2008;19(30):411–419. 5. Schellekens H. Biosimilar therapeutics—what do we need to consider? NDT Plus. 2008;2(Suppl 1):i27–i36. 6. Biotechnology Industry Organization. How do Drugs and Biologics Differ? Biotechnology Industry Organization. http://www.bio.org/articles/how-do-drugs-and-biologics-differ. November 10, 2010. Accessed October 10, 2013. (Created 2/2014) |
||
This article originally appeared on MPR
